Cargando…

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia

PURPOSE: Combination therapy of α-blockers and 5α-reductase inhibitors (5-ARIs) is widely used for the treatment of benign prostatic hyperplasia (BPH). We aimed to study the effect on prostate volume and symptoms of shifting to monotherapy in patients who previously received a combination therapy. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyoung Woo, Moon, Dae Geun, Kim, Hyun Min, Hwang, Jong Ho, Kim, Soon Chan, Nam, Sam Geuk, Park, Jun Tag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212662/ https://www.ncbi.nlm.nih.gov/pubmed/22087362 http://dx.doi.org/10.4111/kju.2011.52.10.681

Ejemplares similares

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
por: Ong, Hueih Ling, et al.
Publicado: (2016)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
por: Xu, Xiao-Feng, et al.
Publicado: (2020)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats
por: Hwangbo, Hyun, et al.
Publicado: (2018)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Benign Prostatic Hyperplasia: from Bench to Clinic
por: Yoo, Tag Keun, et al.
Publicado: (2012)

Personalized therapeutics of α(1)-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Zhu, Ling-ling, et al.
Publicado: (2015)

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
por: Liu, Jiakuan, et al.
Publicado: (2019)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

Mixture of Corni Fructus and Schisandrae Fructus improves testosterone-induced benign prostatic hyperplasia through regulating 5α-reductase 2 and androgen receptor
por: Hwangbo, Hyun, et al.
Publicado: (2023)

Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase
por: Youn, Dong-Hyun, et al.
Publicado: (2016)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia
por: Nickel, J C, et al.
Publicado: (2008)

Combined effect of polymorphisms in type III 5-α reductase and androgen receptor gene with the risk of benign prostatic hyperplasia in Korea
por: Lee, Chung Lyul, et al.
Publicado: (2016)

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
por: Liu, Zhanliang, et al.
Publicado: (2022)

Benign Prostatic Hyperplasia
Publicado: (2015)

Korean clinical practice guideline for benign prostatic hyperplasia
por: Yeo, Jeong Kyun, et al.
Publicado: (2016)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

AB077. The expression and clinical significance of α-actinin-1 in prostate cancer and benign prostatic hyperplasia
por: Cao, Feng-Hong
Publicado: (2017)

Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice
por: Fujita, Takashi, et al.
Publicado: (2023)

Efficacy of Alpha Blocker Treatment According to the Degree of Intravesical Prostatic Protrusion Detected by Transrectal Ultrasonography in Patients with Benign Prostatic Hyperplasia
por: Park, Hee Young, et al.
Publicado: (2012)

Relationship between Intravesical Prostatic Protrusion and Postoperative Outcomes in Patients with Benign Prostatic Hyperplasia
por: Lee, Jong Woo, et al.
Publicado: (2012)

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
por: Cho, Hee Ju, et al.
Publicado: (2014)

Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients
por: Kim, Sung Han, et al.
Publicado: (2021)

Efficacy and Safety of the Selective α(1A)-Adrenoceptor Blocker Silodosin for Severe Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Prospective, Single-Open-Label, Multicenter Study in Korea
por: Moon, Ki Hak, et al.
Publicado: (2014)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea
por: Lee, Young Ju, et al.
Publicado: (2016)

Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model
por: Lee, Gyuok, et al.
Publicado: (2017)

Impact of Changing Trends in Medical Therapy on Surgery for Benign Prostatic Hyperplasia Over Two Decades
por: Choi, Se Young, et al.
Publicado: (2012)

Technical Aspects of Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia
por: Kim, Myong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c1r7io0dn43rlplfkadggk8q1v